MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$30,642K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Share-based compensation
Changes in prepayments and other...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Loss for the period
Changes in accrued expenses and ...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
Revenue
-
32
22,471
Interest income
-
6,473
21,119
Personnel expense
-
10,373
30,415
External r&d expense
-
22,866
62,979
Manufacturing expense
-
9,980
13,321
Regulatory expense
-
545
3,134
Commercial programs
-
4,104
15,192
General and administrative expense
-
3,988
11,386
Depreciation and amortization
-
133
345
Segment adjusted loss before tax
-
-45,484
-93,182
Share-based compensation expense
-
14,023
45,402
Change in fair value - derivatives
-
15,335
3,448
Loss on disposal of property, plant and equipment
-
-
-1
Foreign exchange gains/(losses)
-
-82
13,137
Loss for the period
-48,441
-74,923
-128,896
Depreciation and amortization
62
59
161
Non-cash rent expense
-19
-
3
Fair value change - derivative earnout and warrants
-5,942
15,335
3,448
Loss on disposal of property, plant and equipment
-12
-11
-1
Foreign exchange (gains)/losses
-1,613
-82
13,137
Amortization of premium/discount on available-for-sale debt securities
10
-24
-1,381
Share-based compensation
18,002
14,023
45,402
Changes in prepayments and other receivables
-15,219
10,064
3,216
Changes in accounts payable
-793
5,318
-409
Changes in accrued expenses and other current liabilities
-10,330
5,324
-2,876
Changes in deferred revenue
-
3,987
-6,008
Net cash used in operating activities
-30,604
-40,875
-106,908
Purchase of property, plant and equipment, including internal use software
38
100
146
Maturities of marketable securities
51,000
50,500
71,563
Purchases of marketable securities
62,471
71,541
225,192
Net cash (used in)/provided by investing activities
-11,509
-21,141
-153,775
Transaction costs on issue of ordinary shares and pre-funded warrants-December2024Offering
-
0
1,586
Proceeds from exercise of warrants
651
1,180
458
Proceeds from exercise of options
10,414
12,504
16,964
Net cash provided by financing activities
11,065
13,684
15,836
Net change in cash, cash equivalents and restricted cash
-31,048
-48,332
-244,847
Foreign exchange differences
-1,332
-60
12,819
Cash, cash equivalents and restricted cash at the beginning of the period
491,323
539,715
771,743
Cash, cash equivalents and restricted cash at the end of the period
458,943
491,323
539,715
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from exercise of
options
$10,414K
Proceeds from exercise of
warrants
$651K
Net cash provided by
financing activities
$11,065K
Net change in cash,
cash equivalents and...
-$31,048K
Canceled cashflow
$11,065K
Share-based compensation
$18,002K
Changes in prepayments
and other...
-$15,219K
Foreign exchange
(gains)/losses
-$1,613K
Depreciation and
amortization
$62K
Loss on disposal of
property, plant and...
-$12K
Amortization of
premium/discount on...
$10K
Maturities of marketable
securities
$51,000K
Net cash used in
operating activities
-$30,604K
Net cash (used
in)/provided by investing...
-$11,509K
Canceled cashflow
$34,918K
Canceled cashflow
$51,000K
Loss for the period
-$48,441K
Purchases of marketable
securities
$62,471K
Changes in accrued
expenses and other...
-$10,330K
Fair value change -
derivative earnout and...
-$5,942K
Changes in accounts
payable
-$793K
Non-cash rent expense
-$19K
Purchase of property,
plant and equipment,...
$38K
Buy us a coffee
NewAmsterdam Pharma Co N.V. (NAMSW)
NewAmsterdam Pharma Co N.V. (NAMSW)